Cipla receives EIR from USFDA

Cipla today informed the bourses that it has received an Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA), indicating the closure of the inspection at Invagen (US) manufacturing facility. The agency had conducted inspection from December 2 to 6, 2019.

Besides, USFDA earlier conducted a cGMP inspection at the company’s API manufacturing facility in Bommasandra (Karnataka) from January 20 to 24, 2020. The inspection ended with four observations, which were procedural in nature and none of which were related to data integrity.

The stock of Cipla in today’s trade opened at Rs 466 apiece, as against the previous close of Rs 464.65, but later, it cooled down and at 10.16 am, it was trading at Rs 463.6, down by 0.23 per cent.

Cipla is a global pharmaceutical company which uses cutting-edge technology and innovation to meet the everyday need of all patients.